|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
Nurix Therapeutics, Inc. (NRIX) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
64,411,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
62,735 |
96,901 |
127,870 |
141,861 |
Total Sell Value |
$1,477,070 |
$2,079,250 |
$2,358,554 |
$2,511,464 |
Total People Sold |
3 |
3 |
3 |
4 |
Total Sell Transactions |
9 |
18 |
27 |
42 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Hansen Gwenn |
Chief Scientific Officer |
|
2021-12-01 |
4 |
AS |
$29.13 |
$11,652 |
D/D |
(400) |
14,197 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-12-01 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-11-10 |
4 |
AS |
$32.38 |
$38,856 |
D/D |
(1,200) |
1,286 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-11-10 |
4 |
OE |
$1.86 |
$2,232 |
D/D |
1,200 |
2,486 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-11-01 |
4 |
AS |
$33.24 |
$13,296 |
D/D |
(400) |
14,197 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-11-01 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-10-27 |
4 |
AS |
$35.00 |
$14,000 |
D/D |
(400) |
14,197 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-10-27 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-10-27 |
4 |
AS |
$35.25 |
$28,200 |
D/D |
(800) |
1,286 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-10-27 |
4 |
OE |
$1.86 |
$1,488 |
D/D |
800 |
2,086 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-10-11 |
4 |
AS |
$27.36 |
$32,832 |
D/D |
(1,200) |
1,286 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-10-11 |
4 |
OE |
$1.86 |
$2,232 |
D/D |
1,200 |
2,486 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-10-01 |
4 |
AS |
$29.92 |
$11,968 |
D/D |
(400) |
14,197 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-10-01 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-09-10 |
4 |
AS |
$35.10 |
$71,860 |
D/D |
(2,000) |
1,286 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-09-10 |
4 |
OE |
$1.86 |
$3,720 |
D/D |
2,000 |
3,286 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-09-07 |
4 |
AS |
$35.25 |
$112,800 |
D/D |
(3,200) |
1,286 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-09-07 |
4 |
OE |
$1.86 |
$5,952 |
D/D |
3,200 |
4,486 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-09-07 |
4 |
AS |
$35.00 |
$56,000 |
D/D |
(1,600) |
14,197 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-09-07 |
4 |
OE |
$7.26 |
$11,616 |
D/D |
1,600 |
15,797 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-09-01 |
4 |
AS |
$32.34 |
$12,936 |
D/D |
(400) |
14,197 |
|
- |
|
Hansen Gwenn |
Chief Scientific Officer |
|
2021-09-01 |
4 |
OE |
$7.26 |
$2,904 |
D/D |
400 |
14,597 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-08-10 |
4 |
AS |
$29.87 |
$35,845 |
D/D |
(1,200) |
805 |
|
- |
|
Ring Christine |
General Counsel |
|
2021-08-10 |
4 |
OE |
$1.86 |
$2,232 |
D/D |
1,200 |
2,005 |
|
- |
|
Beaurang Pierre |
Chief Business Officer |
|
2021-08-10 |
4 |
AS |
$29.74 |
$223,926 |
D/D |
(7,500) |
4,330 |
|
- |
|
173 Records found
|
|
Page 4 of 7 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|